Patient Characteristics for Studies Included in the Systematic Review
| Study | No. of patients* | Histologic class | Pretherapy stage† | Type of therapy |
|---|---|---|---|---|
| HD | ||||
| de Wit et al. (25) | 5 | NA | NA | Chemotherapy ± radiotherapy |
| Filmont et al. (16) | 32 | 22 NS, 7 MC, 2 LP, 1 LD | NA | Chemotherapy ± radiotherapy ± surgery or autologous transplantation |
| Foo et al. (26) | 9 | 7 NS, 1 MC, 1 unclassifiable | 8 II, 1 III | Chemotherapy ± radiotherapy |
| Friedberg et al. (17) | 32 | 20 NS, 6 MC, 3 LP, 7 unclassifiable | 3 I, 23 II, 6 III, 4 IV | ABVD or MOPP + ABVD ± radiotherapy |
| Guay et al. (18) | 48 | NA | 2 I, 23 II, 15 III, 8 IV | MOPP or ABVD ± radiotherapy |
| Jerusalem et al. (27,31) | 31 | 27 NS, 3 MC, 1 LD | NA | Chemotherapy ± radiotherapy |
| Keresztes et al. (32) | 26 | NA | NA | C-MOPP + ABVD or C-MOPP + ABV + CEP ± radiotherapy |
| Mikosch et al. (28) | 31 | NA | NA | Chemotherapy ± radiotherapy |
| Mikhaeel et al. (29) | 15 | NA | 8 I + II, 7 III + IV | ABVD ± radiotherapy |
| Mocikova et al. (33) | 71 | NA | NA | Chemotherapy ± radiotherapy |
| Rigacci et al. (19) | 28 | 22 NS, 5 MC, 1 LD | 21 II, 5 III, 2 IV | ABVD ± radiotherapy |
| Schaefer et al. (30) | 18 | 17 NS, 1 MC | NA | NA |
| Spaepen et al. (24) | 60 | 45 NS, 9 MC, 3 LP, 3 unclassifiable | 25 II, 19 III, 16 IV | Stanford V or MOPP + ABV ± radiotherapy |
| Weihrauch et al. (34) | 20 | NA | 1 I, 9 II, 7 III, 2 IV | ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy‡ |
| Wickmann et al. (21) | 48 | NA | NA | GPOH-HD 95§ |
| Aggressive NHL | ||||
| de Wit et al. (25) | 6 | Aggressive by REAL/WHO criteria | NA | Chemotherapy ± radiotherapy |
| Foo et al. (26) | 12 | 11 diffuse large, 1 PTCL | 3 I, 5 II, 2 III, 2 IV | Chemotherapy ± radiotherapy |
| Jerusalem et al. (31) | 35 | 27 DLBCL, 8 FL grade 3 | NA | Chemotherapy ± radiotherapy |
| Juweid et al. (22) | 54 | 47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 1 angioimmunoblastic T-cell | 19 I + II, 35 III + IV | 22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP |
| Mikosch et al. (28) | 24 | Aggressive by REAL/WHO criteria | NA | Chemotherapy ± radiotherapy |
| Mikhaeel et al. (23) | 45 | “Aggressive” (diffuse mixed, diffuse large cell, large cell immunoblastic) | 30 I + II, 19 III + IV‖ | Radiotherapy only or CHOP ± radiotherapy |
| Schaefer et al. (30) | 5 | 5 DLBCL | NA | NA |
| Spaepen et al. (24) | 73 | 50 DLBCL, 8 ALCL, 7 ALCL HD-like, 5 MCL, 3 PTCL | NA | Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases) |
↵* Who met inclusion criteria of this systematic review.
↵† According to Ann Arbor staging system.
↵‡ Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation.
↵§ Treatment strategy for HD in children and adolescents (35).
↵‖ Data abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy.
ALCL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CEP = CCNU, etoposide, prednimustine; C-MOPP = cyclophosphamide, vincristine, procarbazine, prednisone; CNOP = cyclophosphamide, mitoxantrone, vincristine, prednisone; FL = follicular lymphoma; LD = lymphocyte depleted; LP = lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sclerosis; ProMACE-CytaBOM = prednisone, cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate; PTCL = peripheral T-cell lymphoma; R-CHOP = rituximab plus CHOP; Stanford V = doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone; UKSCCG = United Kingdom children cancer study group; WHO = World Health Organization.